吉西他滨组成方案挽救治疗非霍奇金淋巴瘤的疗效与安全性分析

目的:探讨GDP和GemOx方案治疗复发难治性非霍奇金淋巴瘤的早期疗效及安全性。方法:选取本院2016年1月至2017年8月收治的复发难治性弥漫大B细胞淋巴瘤及复发难治性NK/T细胞淋巴瘤患者共52例，其中25例接受 GDP方案化疗，27例接受GemOx方案化疗。观察两组患者早期临床疗效和毒副反应。结果:GDP方案组患者总有效率52.00%，GemOx方案组患者总有效率59.26%。两种方案的主要毒副反应均为轻度的消化道反应、血液学毒性及转氨酶升高。结论:以吉西他滨为基础的联合化疗方案可作为复发难治性非霍奇金淋巴瘤的治疗选择。

The efficacy and safety analysis of gemcitabine composition regimens in the salvage therapy for non-Hodgkin' s lymphoma

Objective:To explore the efficacy and safety of the chemotherapy of GDP and GemOx in relapsed and refractory non-Hodgkin's lymphoma.Methods:52 patients with relapsed and refractory diffuse large B cell lymphoma and NK/T cell lymphoma treated in our hospital from January 2016 to August 2017 were randomly divided into two groups:25 patients received GDP chemotherapy，27 patients received GemOx chemotherapy.The early clinical outcomes and adverse reactions of the two groups patients were observed.Results:The overall remission rate of GDP chemotherapy was 52.00%，and the overall remission rate of GemOx chemotherapy was 59.26%.The main toxicity of two groups included digestive system response，hematologic toxity and abnormal liver function，and the degree was slight.Conclusion:Gemcitabine composition regimens were treatment options for relapsed and refractory non-Hodgkin' s lymphoma.